Alterity Therapeutics Parkinson’s Disease and Multiple System Atrophy Data Featured at the American Academy of Neurology (AAN) 2024 Annual Meeting
April 17, 2024 07:25 ET
|
ALTERITY THERAPEUTICS LIMITED
– ATH434 Improved Motor Performance and General Function in a Primate Model of Parkinson’s Disease – – ATH434-201 Phase 2 Baseline Data Confirm Approach to Target Biomarkers for Slowing...
Novartis Kesimpta® six-year efficacy data show substantial benefits in recently diagnosed treatment- naïve people with relapsing multiple sclerosis
April 17, 2024 01:15 ET
|
Novartis Pharma AG
Continuous Kesimpta® treatment for up to six years showed sustained efficacy in recently diagnosed (≤3 years) treatment-naïve people living with relapsing multiple sclerosis (RMS) in an analysis...
Press Release: New 48-week frexalimab phase 2 data support potential for high sustained efficacy in multiple sclerosis
April 17, 2024 01:00 ET
|
Sanofi - Aventis Groupe
New 48-week frexalimab phase 2 data support potential for high sustained efficacy in multiple sclerosis Data support frexalimab as a potential first-in-class, high-efficacy, non-lymphocyte depleting...
Connect Biopharma Reports Full Year 2023 Financial Results and Provides Business Update
April 16, 2024 16:05 ET
|
Connect Biopharma Holdings Limited
Reported two positive readouts for rademikibart, the Company’s lead asset, from the Global Phase 2b trial in moderate-to-severe persistent asthma and from the China pivotal trial in moderate-to-severe...
Xenon Pharmaceuticals Showcases XEN1101 at the American Academy of Neurology 2024 Annual Meeting
April 16, 2024 08:30 ET
|
Xenon Pharmaceuticals Inc.
VANCOUVER, British Columbia, April 16, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company, announced two oral presentations...
AskBio presents 18-month Phase Ib trial results of AB-1005 gene therapy for patients with Parkinson’s disease
April 16, 2024 08:03 ET
|
Asklepios BioPharmaceutical, Inc. (AskBio)
Berlin, Germany, and Research Triangle Park, NC, USA, April 16, 2024 (GLOBE NEWSWIRE) -- Not intended for UK Media AB-1005 (also known as AAV2-GDNF), an investigational gene therapy for the...
Acumen Pharmaceuticals Presents First Comprehensive Clinical and Biomarker Data for Sabirnetug (ACU193) at American Academy of Neurology 2024 Annual Meeting
April 16, 2024 08:00 ET
|
Acumen Pharmaceuticals, Inc.
Presentation and poster include deeper data insights on sabirnetug safety profile, target engagement and fluid biomarker changesPresentation to be featured during AAN Emerging Science SessionCompany...
Ocular Therapeutix™ Strengthens Clinical Team with Appointment of Key Retinal Leaders
April 16, 2024 07:00 ET
|
Ocular Therapeutix, Inc.
Nadia K. Waheed, MD, MPH, Appointed Chief Medical Officer; Peter K. Kaiser, MD, to Become Chief Development Officer; Andrea Gibson, PhD, Named Vice President, Medical Collaborations; and Namrata...
argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Patients with Debilitating Autoimmune Disease
April 16, 2024 01:00 ET
|
argenx SE
ADHERE data show VYVGART® Hytrulo has potential to be first advancement for CIDP patients in 30 years Real-world data demonstrate gMG patients able to significantly reduce steroid use over first...
Neurona Therapeutics Presents Positive Clinical Update from NRTX-1001 Cell Therapy Trial in Adults with Drug-resistant Focal Epilepsy at American Academy of Neurology (AAN) 2024 Annual Meeting
April 15, 2024 08:00 ET
|
Neurona Therapeutics
NRTX-1001 administration has been well-tolerated in all individuals treated to date 4 of 5 subjects treated with the lower dose of NRTX-1001 report >50% seizure reduction 3 of 5 subjects report...